New antibody tested to fight HIV at earliest stage
NCT ID NCT02591420
Summary
This early-stage study tested the safety and initial effects of an experimental antibody called VRC01 in adults recently diagnosed with HIV. Participants received either the antibody alone, the antibody plus standard antiretroviral therapy (ART), or a placebo plus ART. The main goals were to see if the antibody was safe and if it could help control the virus, especially in the first critical days of infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECHO Center Non-Network CRS
Chon Buri, Thailand
-
Kenya Med. Research Inst./Walter Reed Project, Clinical Research Centre, Off Hospital Road. Kericho
Kericho, 20200, Kenya
-
Makerere University Walter Reed Project (MUWRP)
Kampala, Uganda
-
National Institute for Medical Research (NIMR)-Mbeya Medical Research Center (MMRC) Non-Network CRS
Mbeya, Tanzania
-
SEARCH Thai Red Cross AIDS Research Centre Non-Network CRS
Bangkok, 10330, Thailand
Conditions
Explore the condition pages connected to this study.